BE

Ellen Gomme

This inventor holds 0 USPTO granted patents, plus 3 CIPO patents.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ellen Gomme. Retrieved from https://idiyas.com/inventor/ellen-gomme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Ellen Gomme: Innovator in Neurodegenerative Disease Treatment

Introduction

Ellen Gomme is a notable inventor based in Belgium, recognized for her contributions to the field of neurodegenerative diseases. Her innovative work focuses on developing treatments for conditions such as Parkinson's disease and Alzheimer's disease.

Latest Patents

Ellen Gomme holds a patent for "Thiadiazole Derivatives For The Treatment Of Neuro Degenerative Diseases." This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of various a-synucleopathies, including Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, among others.

Career Highlights

Ellen Gomme has made significant strides in her career, particularly through her work at Nv Remynd. Her research has the potential to impact the lives of many individuals suffering from debilitating neurodegenerative conditions.

Collaborations

Ellen collaborates with talented individuals such as Gerard Griffioen and Kristel Marie Coupet, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Ellen Gomme's work in developing treatments for neurodegenerative diseases showcases her dedication to improving healthcare outcomes. Her innovative approach and collaboration with others in the field highlight the importance of teamwork in scientific advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…